DLA Piper advises Xeltis on strategic cooperation with Grand Pharma
DLA Piper has advised Xeltis AG (Xeltis), a medical device company based in the Netherlands, on its strategic cooperation agreement pertaining to a technology license with Grand Pharmaceutical Group Limited and its subsidiaries (Grand Pharma).
Xeltis will grant an exclusive license to Grand Pharma for the development, production and commercialization rights of aXess, a global innovative endogenous tissue repair product for hemodialysis treatment of Arteriovenous Graft (AVG) patients with End Stage Renal Disease (ESRD) as well as other new products in the field of hemodialysis developed under the same technology platform in Greater China (Mainland China, Hong Kong Special Administration Region, Macau Special Administrative Region and Taiwan Region). DLA Piper also advised Xeltis with respect to Grand Pharma’s strategic equity investment in the company.
Xeltis is a clinical-stage company that develops supramolecular polymer-based endogenous tissue restoration (ETR) devices for vascular-related treatments. The Xeltis medical device platform comprises innovative bioabsorbable heart valves and blood vessels, designed to enable ETR: the natural restoration of the complex body parts that are replaced upon implantation.
Commenting on the co-operation arrangement, Ting Xiao, Partner and Co-Head of Life Sciences in China said: “DLA Piper was delighted to advise Xeltis on this agreement. aXess is a truly innovative product and the cooperation between Xeltis and Grand Pharma will benefit many Chinese hemodialysis patients.”
The DLA Piper team was jointly led by Ting Xiao, IPT Partner, and Qiang Li, Corporate Partner, both based in Shanghai. Ting and Qianq were supported by Alex Zhuo, Of Counsel, Corporate, in Hong Kong, as well as Consultants Zhiyuan Wu, Corporate and Jiayi Wang, IPT, both based in Shanghai. Windson Li, Co-Head of Tax, Asia, and Kelvin Chen, Head of International Arbitration, China, both provided additional advice in their respective areas.
